- The Wall St. Journal Health Blog had an interesting post Thursday on how Genzyme’s struggle to produce enough Myozyme heightens worries about generic biotech drugs.
- The New York Times published an interesting article Wednesday on the recent "tidal wave" and the coming "golden era" of generic drugs.
- Novartis lost its challenge to India’s drug patent law on Monday (see New York Times; Business Week; WSJ Health Blog). PhRMA reacted in this press release.
- The Spicy IP blog has been providing a thoughtful, in-depth perspective on the Novartis India case.
- FDA Law Blog reported Monday that the House passed an FDA appropriations bill with a provision allowing for reimportation of prescription drugs.
- MarketWatch.com had this interesting article Monday on recent growth in pharmaceutical R&D in China and India.
Recent Posts
- Hikma v. Vanda: Oral Argument Recap
- Teva v. Lilly should not be read as creating a new 112 rule for method of use claims
- Should ANDA filers be using the PTAB to mount early challenges to OB patents?
- Switching to WordPress
- Judge Hughes concurrence highlights post grant review appeal standing issue for pharma cases
Posted in Pharma Business News
One response to “Pharma News Briefs”
-
The WSJ Health Blog item was interesting, but I think it missed the boat where the comparison to biogenerics is concerned. As I commented over there, the real issue is that the biotech industry wants to have it both ways with respect to complex protein drugs. They want generic versions to undergo expensive clinical testing, but when an established like Genzyme has trouble making equivalent batches of a drug in different plants, it’s perfectly OK to rely on a battery of pre-clinical assays to determine equivalence. Why not apply the same rules to both established biotechs and would-be generic entrants? That’s effectively what the congressional biogenerics bills do, after all.
I wrote more on the subject at the following link:LikeLike
Orange Book Blog 
Leave a reply to David Hamilton Cancel reply